Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Dodge & Cox Stock I

Vanguard PRIMECAP Inv

Vanguard PRIMECAP Core Inv

Janus Henderson Global Life Sciences D

Janus Henderson Global Life Sciences

Loomis Sayles Large Cap Growth Trust C

Dimensional International Value ETF

Burgundy European Equity Composite

American Funds American Mutual A

Capital Group American Mutual Comp

Janus Henderson Glb Life Scn I2 USD

Janus Global Life Science AUSD

DFA International Core Equity I

Hartford Dividend and Growth Y

Vanguard Capital Opportunity Inv

Principal Equity Income A

Loomis Sayles Growth Y

Franklin Mutual Global Discovery Z

Russell Investments Core Equity SMA

Franklin Mutual Shares Z

Dodge & Cox

PRIMECAP Management Company

Principal Financial Group Inc

Renaissance Technologies Corp

Cullen Capital Management, LLC

Wells Fargo & Co

Envestnet Asset Management Inc

BlackRock Inc

Northern Trust Corp

Fisher Asset Management, LLC

State Street Corp

UBS Group AG

Dimensional Fund Advisors, Inc.

Morgan Stanley - Brokerage Accounts

Loomis, Sayles & Company LP

Bank of America Corp

Franklin Resources Inc

Wellington Management Company LLP

Goldman Sachs Group Inc

HHG PLC

Novartis AG ADR

Dr. Vasant  Narasimhan M.D.

Chief Executive Officer

Mr. Harry  Kirsch

Chief Financial Officer

Mr. Victor  Bulto

President of US

Dr. Patrick  Horber M.D.

President of International

Dr. Steffen  Lang Ph.D.

President of Operations

Paul  Penepent

Head of Group Financial Reporting and Accounting

Ms. Sloan  Simpson

Global Head of Investor Relations

Dr. Klaus  Moosmayer Ph.D.

Chief Ethics, Risk & Compliance Officer

Ms. Karen L. Hale

Chief Legal Officer

Dr. Robert  Kowalski Pharm.D.

Chief People & Organization Officer

NVS's next earnings is on January 31, 2025 (Before Market Open)

NVS's latest dividend is 3.777 USD on March 7, 2024

Novartis AG ADR (NVS) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Novartis AG ADR (NVS) Earnings Report Date and History | NYSE

NVS's next earnings is on January 31, 2025 (Before Market Open)

When is the earnings report for NVS?

NVS Earnings History

NVS's latest dividend is 3.777 USD on March 7, 2024

NVS Stock Discussion Forum and Message Board

News for NYSE: NVS